Joban Vaishnav, MD
- Director, Johns Hopkins Comprehensive Amyloidosis Center
- Assistant Professor of Medicine
Our multidisciplinary team consists of cardiologists, neurologists, oncologists, genetic counselors, gastroenterologists and nephrologists, ensuring collaborative, comprehensive treatment for amyloidosis, including its cardiac manifestations. We strive to provide quick diagnoses and top-notch patient care while researching new and innovative treatment options.
Why Choose Johns Hopkins for Amyloidosis Care?
Find out what sets our clinic apart.
Multidisciplinary Team
Our clinic features leading experts in a variety of fields that coordinate with referring physicians to provide holistic treatment plans.
Heart Failure Bridge Clinic
We collaborate closely with the Heart Failure Bridge Clinic, which facilitates on-demand appointments. In this clinic we can often accommodate you within a short timeframe for your symptoms.
Cutting-edge Research
Our team conducts clinical trials to develop new treatment options and offers patient registries for longitudinal studies.
Abby Hubbard, C.R.N.P., C.H.F.N.
Infiltrative Cardiomyopathy Nurse Practitioner
Kate Campion, DNP, AGACNP
Outpatient Oncology Nurse Practitioner
Hematologic Malignancies: Multiple Myeloma and AL amyloidosis
Emily Brown, M.G.C., C.G.C.
Genetic Counselor
Appointment Phone: 410-502-2578
-
Jose Manuel Monroy Trujillo, MD
- Associate Program Director, Nephrology Fellowship
- Assistant Professor of Medicine
Our Research
-
- A Phase 3, Randomized, Multicenter, Double-Blind, Placebo Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis [NEOD001-301]
- Status, Active, enrolling
- A Phase 3, Randomized, Multicenter, Double-Blind, Placebo Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis [NEOD001-301]
-
- A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02 (NCT01961921)
- Status: Complete
- APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP) (NCT01960348)
- Status: Complete
- A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM) (NCT01994889)
- Status: Complete
- APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) (NCT03997383)
- Status: Active, not recruiting
- A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (NCT04136184)
- Status: Active, not recruiting
- HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) (NCT03759379)
- Status: Active, not recruiting
- HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) (NCT04153149)
- Status: Active, not recruiting
- A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02 (NCT01961921)
-
Overview: This research project investigates targeting the PKG/Chip signaling nexus to attenuate transthyretin cardiac amyloidosis.
Significance: We identified a pathway that is uniquely reduced in transthyretin cardiac amyloidosis and we hope by stimulating PKG and Chip that we will improve upon current therapeutic strategies and the outcomes for cardiac amyloidosis patients.
Innovation: This program explores a novel mechanism to increase the degradation of transthyretin once it is taken up by the myocardium thereby reducing the burden on the heart while enhancing the function of the heart.
Impact: Increasing the removal of transthyretin in the heart is not achievable with current pharmacological strategies. Our study addresses this need by providing a new therapeutic approach to better treatment for cardiac amyloidosis patients.
Locations
We provide appointments for amyloidosis patients at Johns Hopkins Bayview Medical Center and the Levi Watkins, Jr, MD, Outpatient Center in Baltimore.
Johns Hopkins Bayview Medical Center
4940 Eastern Ave
Baltimore, MD 21224
Levi Watkins, Jr, MD, Outpatient Center
601 N. Caroline St
Baltimore, MD 21287
Make a Donation
Support our researchers' and physicians' ongoing efforts to prevent cardiovascular disease by making a donation online, by phone or by mail.
Online
Make a donation now or pledge to give later. Fill out our secure online giving form.
Over the Phone
Call us at 410-907-5010 to speak to someone directly about making a donation.
Download our charitable giving form and mail it to our development office.
Patient Support Resources
For more information on amyloidosis and to find support groups, check out the resources below.
Amyloidosis Support Groups Amyloidosis Research Consortium Amyloidosis Foundation
You are being redirected to a website outside Johns Hopkins for information purposes only. Johns Hopkins is not responsible for any aspect of the external website.